The production index of Pharmstandard-UfaVITA OJSC for the first seven months of this year exceeded 180%.
According to the press service of the Government of the Republic of Bashkortostan, Bashkiria quadrupled its production of medicines in July this year. The growth of the republic's pharmaceutical production was due to manufacturing the coronavirus vaccines and other medicinal products.
'The increase in the industrial production index was expected. Our region's leading pharmaceutical companies—Immunopreparat (the Ufa branch of NPO Microgen JSC) and Pharmstandard-UfaVITA OJSC—are being actively developed and modernised; they are at the frontline in today's challenging epidemiological situation while supplying vaccines against the coronavirus infection and other infectious diseases', says Minister of Industry of the Republic of Bashkortostan Aleksandr Sheldyaev.
The production index of Pharmstandard-UfaVITA OJSC for the first seven months of this year exceeded 180%. The enterprise accommodates facilities for the production (filling and packaging) of the Sputnik V (GAM-COVID-Vac) and Sputnik Light vaccines against COVID-19. According to the official website of the Government of the Republic of Bashkortostan, the available capacities are sufficient to produce up to 40 million vaccine doses monthly.
The company is also implementing a number of major investment projects. Since the beginning of the year, it has invested 710 million roubles in fixed assets, which corresponds to the 19.5% increase compared to the 2020 level. About 250 million roubles have been invested in a project related to developing a pre-treatment facility for industrial and household wastewater. Another 60 million are planned to be invested in a new workshop No. 6, this year. This new facility will be used for the production of film- and sugar-coated, as well as uncoated solid dosage forms; SATs and commissioning works of the manufacturing equipment are already underway. Putting the production site into operation will allow to create up to 100 additional jobs and produce up to 3 billion tablets annually. The facility is expected to contribute 200 million roubles to the treasury and non-budgetary funds every year. Investments in the project have already totalled 1.347 billion roubles.
In 2020, Pharmstandard-UfaVITA OJSC commissioned a facility for the aseptic production of sterile medicines in polymer dropper vials and plastic ampoules. This allowed for expanding the company's product range and creating capacities for the production of new medicines in vials and ampoules with the use of the BFS technology. Investments in the project exceeded 800 million roubles. The facility's total annual production capacity is over 33 million vials and over 47 million drops and injection solutions in ampoules. The production site is expected to contribute 160 million roubles to the treasury and non-budgetary funds every year. The company is currently building a new site for the production of the blood coagulation factor VIII medication. The project is planned to receive 1.14 billion roubles in investments in 2021. It is to be launched in Q3 2022. In total, the company plans to invest 1.57 billion roubles in the project.